HDBuzz

Skyhawk Therapeutics have received the regulatory approval needed to broaden its FALCON-HD trial to include the United States, Canada, and the UK. The expanded trial will enroll up to 400 more people with Stage 2 and early Stage 3 HD across more than 40 sites worldwide.

Roche announced it is stopping development of two of its huntingtin-lowering ASO drugs, tominersen and RG6496. This marks a disappointing end to an important chapter in HD clinical research. en.hdbuzz.net/roche-ends-two…

First participant dosed in pioneering neural stem cell trial for Huntington’s disease
A new clinical trial for HD is underway. The first participant has been dosed in REGEN4HD, a study testing whether transplanting neural stem cells is safe as a potentia… ift.tt/LTCh07A

Evolving Needs, Evolving Care: Adapting Psychological Support Across Different Stages of Huntington’s Disease
⏱️ 9 min read | Huntington’s disease affects more than movement: it also has a major impact on mental health. Researchers explore why psychologi… ift.tt/g8CA3PV

Sealing the gap: a case for slower, smarter DNA repair
⏱️ 7 min read | Your body assembles DNA like a team of workers who set and bond a pattern of tiles. A recent study shows that one special assistant might slow somatic CAG expansion and delaying HD on… ift.tt/mnjeTal